{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eylea&page=5",
    "query": {
      "intervention": "Eylea",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 269,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eylea&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eylea&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T21:12:08.438Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02457026",
      "title": "Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone Acetonide",
          "type": "DRUG"
        },
        {
          "name": "Verteporfin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-01",
      "completion_date": "2018-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-26",
      "last_synced_at": "2026-10-19T21:12:08.438Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02457026"
    },
    {
      "nct_id": "NCT00396591",
      "title": "AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2006-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2013-01-10",
      "last_synced_at": "2026-10-19T21:12:08.438Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00396591"
    },
    {
      "nct_id": "NCT00369655",
      "title": "VEGF Trap in Treating Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ziv-aflibercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2007-01",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2014-05-05",
      "last_synced_at": "2026-10-19T21:12:08.438Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00369655"
    },
    {
      "nct_id": "NCT04684394",
      "title": "A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Retinal Disease",
        "Retinal Degeneration",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "GEM103",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gemini Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2020-12-29",
      "completion_date": "2022-02-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-31",
      "last_synced_at": "2026-10-19T21:12:08.438Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Campbell, California • Encino, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684394"
    },
    {
      "nct_id": "NCT01710332",
      "title": "The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Serous Chorioretinopathy"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-10",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-06-16",
      "last_synced_at": "2026-10-19T21:12:08.438Z",
      "location_count": 2,
      "location_summary": "Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Huntingdon Valley",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01710332"
    },
    {
      "nct_id": "NCT03810313",
      "title": "Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Central Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Brolucizumab 6 mg",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Sham injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 493,
      "start_date": "2019-07-03",
      "completion_date": "2021-07-26",
      "has_results": true,
      "last_update_posted_date": "2023-01-30",
      "last_synced_at": "2026-10-19T21:12:08.438Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03810313"
    },
    {
      "nct_id": "NCT01521559",
      "title": "Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Branch Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Macular Laser Photocoagulation",
          "type": "PROCEDURE"
        },
        {
          "name": "Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 183,
      "start_date": "2012-04",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2014-11-13",
      "last_synced_at": "2026-10-19T21:12:08.438Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01521559"
    },
    {
      "nct_id": "NCT05989126",
      "title": "Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema (DME)",
        "Neovascular Age-Related Macular Degeneration (nAMD)"
      ],
      "interventions": [
        {
          "name": "aflibercept 8 mg PFS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2024-04-15",
      "completion_date": "2024-05-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-19T21:12:08.438Z",
      "location_count": 2,
      "location_summary": "Bellaire, Texas • The Woodlands, Texas",
      "locations": [
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05989126"
    },
    {
      "nct_id": "NCT01627249",
      "title": "Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "2.0 mg intravitreal aflibercept",
          "type": "DRUG"
        },
        {
          "name": "1.25 mg intravitreal bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "0.3 mg intravitreal ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 660,
      "start_date": "2012-08",
      "completion_date": "2019-04-18",
      "has_results": true,
      "last_update_posted_date": "2020-08-10",
      "last_synced_at": "2026-10-19T21:12:08.438Z",
      "location_count": 90,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Loma Linda, California + 72 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01627249"
    },
    {
      "nct_id": "NCT07496567",
      "title": "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration",
        "Age-Related Macular Degeneration",
        "Choroidal Neovascularization",
        "Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Tiespectus",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyeBiotech Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 960,
      "start_date": "2026-04-15",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-19T21:12:08.438Z",
      "location_count": 52,
      "location_summary": "Gilbert, Arizona • Encino, California • Mountain View, California + 49 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07496567"
    }
  ]
}